Geographic atrophy is an advanced form of dry age-related macular degeneration that causes vision loss in older adults. Until recently, there were no treatments available to target the root cause.

According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational ...

CHICAGO -- An investigational dual-action inhibitor for geographic atrophy (GA) significantly slowed disease progression and ...

“These are devastating diseases with limited treatment options,” said Curt Breneman, Ph.D., dean of Rensselaer’s School of ...

Meibomian gland dysfunction (MGD) is the major cause of evaporative dry eye disease (EDED ... changes that are detected in human subjects. Atrophic glands also showed evidence of epithelial ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has dosed its first patient in a clinical trial for its innovative ...

While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA ... Medicines Agency (EMA), to bring the treatment to patients with GA. The detour for Izervay ...

LumiThera, Inc. today announced the U.S. FDA has authorized marketing of Valeda® Light Delivery System for patients with dry AMD.

Posterial Cortical Atrophy, sometimes called Benson’s disease, is a rare degenerative brain condition that affects the back ...